(Q33831652)

English

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals (English)

1 reference

Europe PubMed Central

29 July 2017

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Raymond F. Schinazi

3

object named as

Raymond F Schinazi

1 reference

Europe PubMed Central

29 July 2017

2

object named as

Mark S Sulkowski

1 reference

Europe PubMed Central

29 July 2017

1

object named as

Liesl M Hagan

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

14 May 2014

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

60

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

37-45

1 reference

Europe PubMed Central

29 July 2017

HCV direct-acting antiviral agents: the best interferon-free combinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Pharmacokinetics of new oral hepatitis C antiviral drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Health-state utilities in liver disease: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Estimation of utilities for chronic hepatitis C from SF-36 scores

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Limited success of HCV antiviral therapy in United States veterans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

4 July 2018

Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Reversibility of hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Liver transplantation in the United States, 1999-2008.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27151

21 January 2018

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

29 October 2018

Liver transplantation for hepatitis C virus-related cirrhosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077973

29 October 2018

Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/24677184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24677184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/HEP.27151

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33831652&oldid=2117501042"